Published in J Nucl Med on June 01, 2011
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol (2016) 1.32
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol (2013) 1.30
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging (2012) 1.14
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol (2015) 1.06
Brain tumors. Semin Nucl Med (2012) 1.05
Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging (2014) 1.04
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol (2012) 1.02
MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging (2012) 0.99
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol (2015) 0.99
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol (2012) 0.94
PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA (2012) 0.89
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol (2014) 0.88
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One (2014) 0.87
Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res (2014) 0.85
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma. PLoS One (2015) 0.81
[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin (2015) 0.81
An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One (2014) 0.80
Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. Eur J Nucl Med Mol Imaging (2015) 0.80
Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. Case Rep Oncol (2012) 0.80
Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. PLoS One (2016) 0.80
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget (2016) 0.78
Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas. Radiat Oncol (2016) 0.77
Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. Eur J Nucl Med Mol Imaging (2015) 0.77
Towards standardization of (18)F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res (2017) 0.77
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? Front Neurol (2016) 0.76
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. PLoS One (2016) 0.75
Follow-Up Imaging: Molecular Imaging is Likely Best as a Single Modality, but Multimodality Imaging is the Future. Front Neurol (2015) 0.75
Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging (2016) 0.75
²³Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note. Neuroradiology (2014) 0.75
Amino acid PET and MR perfusion imaging in brain tumours. Clin Transl Imaging (2017) 0.75
Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. Eur J Nucl Med Mol Imaging (2017) 0.75
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines (2016) 0.75
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med (2007) 3.98
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Terminology of psychogenic nonepileptic seizures. Epilepsia (2015) 3.23
Standardized computer-based organized reporting of EEG: SCORE. Epilepsia (2013) 2.84
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
Transcranial magnetic stimulation and sleep disorders: pathophysiologic insights. Sleep Med (2013) 2.58
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord (2009) 2.28
Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.22
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
The visual word form area and the frequency with which words are encountered: evidence from a parametric fMRI study. Neuroimage (2004) 1.97
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging (2011) 1.89
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol (2010) 1.87
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology (2015) 1.84
Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia (2013) 1.77
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging (2013) 1.63
The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia (2008) 1.62
Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia (2011) 1.58
Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol (2003) 1.50
Successful surgery in late onset epilepsy with tuberous sclerosis complex. Epileptic Disord (2009) 1.49
Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res (2004) 1.48
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology (2014) 1.46
Comparison of cyanamide and placebo in the treatment of alcohol dependence of adolescents. Alcohol Alcohol (2003) 1.46
Retracted A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. J Psychopharmacol (2003) 1.44
The proceedings of the First London Colloquium on Status Epilepticus--University College London, April 12-15, 2007. Introduction. Epilepsia (2007) 1.40
Do visual perspective tasks need theory of mind? Neuroimage (2005) 1.38
Taxi vs. taksi: on orthographic word recognition in the left ventral occipitotemporal cortex. J Cogn Neurosci (2007) 1.37
Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res (2008) 1.36
Thinking of mental and other representations: the roles of left and right temporo-parietal junction. Soc Neurosci (2006) 1.35
Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol (2006) 1.32
Developmental dyslexia: gray matter abnormalities in the occipitotemporal cortex. Hum Brain Mapp (2008) 1.30
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol (2013) 1.30
Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab (2005) 1.29
Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther (2007) 1.29
Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol (2002) 1.27
Temporo-parietal junction activity in theory-of-mind tasks: falseness, beliefs, or attention. J Cogn Neurosci (2009) 1.24
Mutant sodium channel for tumor therapy. Mol Ther (2009) 1.22
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
Evidence for a dysfunction of left posterior reading areas in German dyslexic readers. Neuropsychologia (2006) 1.19
Language lateralization in temporal lobe epilepsy: a comparison between fMRI and the Wada Test. Epilepsia (2006) 1.18
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One (2008) 1.16
Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage (2010) 1.15
Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation. Arch Neurol (2005) 1.15
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Differential SELEX in human glioma cell lines. PLoS One (2009) 1.13
MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics (2005) 1.11
68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med (2009) 1.10
Status epilepticus--making progress. Epilepsia (2011) 1.06
Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging (2010) 1.03
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging (2006) 1.03
(68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging (2014) 1.03
Ischaemic tolerance: a window to endogenous neuroprotection? Lancet (2003) 1.03
Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging (2009) 1.02
Methods to monitor gene therapy with molecular imaging. Methods (2009) 1.02
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther (2005) 1.01
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol (2013) 1.01
Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia (2013) 1.00
A review of transcranial magnetic stimulation in the in vivo functional evaluation of central cholinergic circuits in dementia. Dement Geriatr Cogn Disord (2011) 0.99
Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol (2008) 0.99
Deactivation of the default mode network as a marker of impaired consciousness: an fMRI study. PLoS One (2011) 0.98
Functional brain reorganization after spinal cord injury: systematic review of animal and human studies. Brain Res (2013) 0.98
The established status epilepticus trial 2013. Epilepsia (2013) 0.97
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discov Today (2011) 0.96
Effect of transcranial brain stimulation for the treatment of Alzheimer disease: a review. Int J Alzheimers Dis (2011) 0.96
Stimulating music increases motor coordination in patients afflicted with Morbus Parkinson. Neurosci Lett (2004) 0.96
Thiamine deficiency induced neurochemical, neuroanatomical, and neuropsychological alterations: a reappraisal. ScientificWorldJournal (2013) 0.96
Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol (2009) 0.95
Predictors for negative attitudes toward subjects with epilepsy: a representative survey in the general public in Austria. Epilepsia (2005) 0.95
Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med (2009) 0.94
Diagnosis and treatment of paroxysmal dyskinesias revisited. Ther Adv Neurol Disord (2008) 0.94
[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol (2009) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol (2004) 0.94
The translocator protein ligand [¹⁸F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging (2012) 0.94
Subdural hematoma in a patient with spontaneous intracranial hypotension and cerebral venous thrombosis. Neurol Sci (2010) 0.94
Nonconvulsive status epilepticus and coma. Epilepsia (2009) 0.93
On the functional neuroanatomy of visual word processing: effects of case and letter deviance. J Cogn Neurosci (2009) 0.93
Virtual neck exploration: a new method for localizing abnormal parathyroid glands. Ann Surg (2009) 0.92
Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation (2003) 0.92
Invasive and non-invasive brain stimulation for treatment of neuropathic pain in patients with spinal cord injury: a review. J Spinal Cord Med (2013) 0.92
Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes (2009) 0.91
NUMB does not impair growth and differentiation status of experimental gliomas. Exp Cell Res (2011) 0.90
Medial temporal lobe activation during semantic language processing: fMRI findings in healthy left- and right-handers. Brain Res Cogn Brain Res (2003) 0.90
Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology (2013) 0.90
Lacosamide as a new treatment option in status epilepticus. Epilepsia (2013) 0.90
Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.89